Charles River Laboratories International, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $995.8M | $994.2M | $1.00B | $1.03B | $984.2M | $1.00B | $1.01B |
| Cost of Revenue | — | — | — | — | — | — | — | $660.7M |
| Gross Profit | — | — | — | — | — | — | — | $349.0M |
| Gross Margin | — | — | — | — | — | — | — | 34.6% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $228.9M | $159.4M | $196.1M | $177.6M | $191.5M | $177.8M | $195.7M | $199.2M |
| Operating Income | $119.9M | $119.9M | $-283.4M | $133.8M | $100.1M | $74.7M | $-167.7M | $117.4M |
| Operating Margin | 11.9% | 12.0% | -28.5% | 13.3% | 9.7% | 7.6% | -16.7% | 11.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $53.9M | $-15.1M | $-17.8M | $31.6M | $18.7M | $10.1M | $-3.0M | $20.9M |
| Net Income | $-1.5M | $-14.8M | $-276.6M | $54.4M | $52.3M | $25.5M | $-214.5M | $69.7M |
| Net Margin | -0.1% | -1.5% | -27.8% | 5.4% | 5.1% | 2.6% | -21.4% | 6.9% |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 |
| Shares Outstanding (Basic) | 48.0M | 49.0M | 49.6M | 49.2M | 49.1M | 50.7M | 51.4M | 51.4M |
| Shares Outstanding (Diluted) | 48.0M | 49.0M | 49.6M | 49.4M | 49.3M | 50.9M | 51.6M | 51.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |